About Cuorips
Cuorips is a company based in Chuo (Japan) founded in 2017.. Cuorips has raised $13.18 million across 1 funding round from investors including Osaka University, JIC Venture Growth Investments and JAFCO Group. The company has 56 employees as of March 31, 2024. Cuorips operates in a competitive market with competitors including Mercator MedSystems, Vesigen Therapeutics, Nectero Medical, Amarna Therapeutics and PharmaIN, among others.
- Headquarter Chuo, Japan
- Employees 56 as on 31 Mar, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name Cuorips Inc.
-
Annual Revenue
$1.12 M (USD)658.4as on Mar 31, 2024
-
Net Profit
$-4.11 M (USD)-1.92as on Mar 31, 2024
-
EBITDA
$-3.27 M (USD)0.93as on Mar 31, 2024
-
Total Equity Funding
$13.18 M (USD)
in 1 rounds
-
Latest Funding Round
$13.18 M (USD), Series A
Mar 15, 2021
-
Investors
Osaka University
& 4 more
-
Employee Count
56
as on Mar 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Cuorips
Cuorips is a publicly listed company on the TSE with ticker symbol 4894 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Cuorips
Cuorips has successfully raised a total of $13.18M through 1 strategic funding round. The most recent funding activity was a Series A round of $13.18 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $13.2M
-
First Round
First Round
(15 Mar 2021)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2021 | Amount | Series A - Cuorips | Valuation | JIC Venture Growth Investments |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Cuorips
Cuorips has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Osaka University, JIC Venture Growth Investments and JAFCO Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund focused on growth stage companies
|
Founded Year | Domain | Location | |
|
VC firm investing in Japan and the US
|
Founded Year | Domain | Location | |
|
Buyouts are targeted through venture capital and private equity investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Cuorips
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Cuorips
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cuorips Comparisons
Competitors of Cuorips
Cuorips operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Mercator MedSystems, Vesigen Therapeutics, Nectero Medical, Amarna Therapeutics and PharmaIN, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Catheter-guided microfluid injection systems are developed for targeted tissue therapies.
|
|
| domain | founded_year | HQ Location |
Non-viral delivery platform for intracellular therapeutics using ARMMs technology
|
|
| domain | founded_year | HQ Location |
An endovascular device for treating abdominal aortic aneurysms is developed.
|
|
| domain | founded_year | HQ Location |
Viral gene delivery vectors are developed for diverse diseases.
|
|
| domain | founded_year | HQ Location |
Proprietary drug delivery platforms are developed for API enhancement.
|
|
| domain | founded_year | HQ Location |
Artificial membrane platforms are utilized for vaccine and antibody production.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cuorips
Frequently Asked Questions about Cuorips
When was Cuorips founded?
Cuorips was founded in 2017 and raised its 1st funding round 4 years after it was founded.
Where is Cuorips located?
Cuorips is headquartered in Chuo, Japan. It is registered at Chuo, Yamanashi Prefecture, Japan.
Who is the current CEO of Cuorips?
Takayuki Kusanagi is the current CEO of Cuorips.
Is Cuorips a funded company?
Cuorips is a funded company, having raised a total of $13.18M across 1 funding round to date. The company's 1st funding round was a Series A of $13.18M, raised on Mar 15, 2021.
How many employees does Cuorips have?
As of Mar 31, 2024, the latest employee count at Cuorips is 56.
What is the annual revenue of Cuorips?
Annual revenue of Cuorips is $1.12M as on Mar 31, 2024.
What does Cuorips do?
Cuorips was founded in 2017 in Chuo City, Japan, within the biotechnology sector focused on cardiovascular treatments. A proprietary drug delivery platform for heart failure is developed by the company. iPS cell-derived cardiomyocyte sheets form the core of this platform, which are cultivated and then grafted onto affected hearts to support improved cardiac function. Operations center on advancing this regenerative approach for clinical application.
Who are the top competitors of Cuorips?
Cuorips's top competitors include Mercator MedSystems, Vesigen Therapeutics and PharmaIN.
Is Cuorips publicly traded?
Yes, Cuorips is publicly traded on TSE under the ticker symbol 4894.
Who are Cuorips's investors?
Cuorips has 5 investors. Key investors include Osaka University, JIC Venture Growth Investments, JAFCO Group, Forum for Innovative Regenerative Medicine, and Nippon Venture Capital.
What is Cuorips's ticker symbol?
The ticker symbol of Cuorips is 4894 on TSE.